<p>动量投资者依赖敏锐的分析和时机组合来最大化收益。虽然这种方法可能带来相当大的风险，但识别快速增长的股票并参与一个有继续空间的上涨行情的吸引力是强大的。</p>
<p>生物制药行业所特有的爆炸性增长潜力使其成为许多动量投资者的主要目标，而该领域的两家公司最近取得了显著的收益。第一家是 uniQure N.V. NASDAQ: QURE，在九月底股价大幅跃升，并努力在接下来的一个月中继续保持这些收益。另一家是 Omeros Corp. NASDAQ: OMER，在十月中旬经历了股价的跳升。</p>
<p>对于寻求在生物技术领域之外进行多元化投资的投资者来说，Stardust Power Inc. NASDAQ: SDST 是一家微型市值电池技术公司，尚未开始上涨，但根据乐观分析师的估计，其潜在上行空间巨大。</p>
<h2>大量管线和有希望的结果推动 uniQure</h2>
<p>uniQure 以其用于设计基因疗法的腺病毒相关病毒（AAV）载体平台而闻名，该平台用于治疗包括血友病在内的疾病。uniQure 在九月份报告了其 AMT-191 候选药物的初步安全性和探索性疗效试验的令人鼓舞的结果。该公司还有多种其他药物候选者显示出希望：其 AMT-130 在今年早些时候获得了关键的突破性疗法认证，并在亨廷顿病患者中显示出强劲的结果，而 AMT-260 在一种独特类型的癫痫患者中显示出显著减少癫痫发作的效果。</p>
<p>对于像 uniQure 这样的尚未盈利的生物技术公司来说，保持健康的现金储备以支持其在关键开发和试验阶段的运营至关重要。截至第二季度末，该公司拥有 3.77 亿美元的现金和投资，为其运营提供了持续到 2027 年的资金，并超出了 AMT-130 的预计上市时间。</p>
<p>自九月激增以来，QURE 的股价一直横盘交易，但分析师们仍然持乐观态度。12 位分析师中有 10 位将该股票评级为买入，他们共同预计的共识目标价为 71.75 美元，具有 15% 的上行潜力。</p>
<h2>诺和诺德重大交易为 Omeros 开启机会</h2>
<p>Omeros 开发针对中枢神经系统相关疾病的小分子和蛋白质治疗药物。其最有前景的药物之一 Zaltenibart 有潜力解决多种血液和肾脏疾病。</p>
<p>在十月中旬，该公司的股价在宣布丹麦跨国制药巨头诺和诺德 A/S NYSE: NVO 以 2.4 亿美元的预付款和潜在的额外版税收购 Zaltenibart 的许可权时激增。</p>
<p>虽然这对 Omeros 来说是个重大消息，但仍然可能有进一步上涨的空间。由于该公司现在有资金支持到 2027 年，它还有额外的时间来追求 FDA 对其另一款顶级候选药物 Narsoplimab 的批准。</p>
<p>尽管在诺和诺德消息公布后，OMER 的股价从每股略高于 4 美元跃升至接近 11 美元，但在激增后，OMER 的股价已回落至每股约 8 美元。尽管如此，分析师们仍持乐观态度，八位分析师中有五位将 OMER 评级为买入。他们看到近 244% 的上行潜力，这将使 OMER 的股价超过每股 27 美元。</p>
<h2>关键协议和监管利好可能意味着 Stardust 有 1000% 的上行空间</h2>
<p>尚未盈利的生物制药公司是一项风险投资，但 Stardust 可能更具风险。这家成立仅三年、尚未产生收入的 4000 万美元锂电池产品供应商今年下跌超过 87%。然而，由于与 Oklahoma Gas and Electric Company（OGE Energy Corp. NYSE: OGE 的子公司）达成的协议，开发电力变电站，以及与 Prairie Lithium 达成的协议，确保每年 6000 公吨的碳酸锂供应，该公司可能有望实现增长。</p>
<p>随着这些进展，Stardust 将在国内需求激增和国际贸易紧张局势限制北美锂供应的时刻，离扩大生产更近一步。</p>
<p>此外，联邦倡议帮助增强了国内锂生产商的实力，为像 Stardust 这样的公司提供了进一步的利好。这促使分析师对 SDST 股票持大胆乐观的看法。六位分析师中有四位将 SDST 评级为买入，该公司的目标价为 51.13 美元，令人惊讶的是，几乎是其当前交易价格的 1000% 之上。</p>
<h2>你现在应该投资 1000 美元在 uniQure 吗？</h2>
<p>在你考虑 uniQure 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 uniQure 并不在名单上。</p>
<p>虽然 uniQure 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

奥麦罗制药

QURE

SDST

<p>三只股票正在吸引动量投资者的关注：uniQure N.V. (QURE) 在九月份经历了显著的价格上涨，Omeros Corp. (OMER) 在与诺和诺德达成许可协议后在十月份大幅上涨，以及 Stardust Power Inc. (SDST)，这是一家微型市值的电池技术公司，潜在涨幅接近 1000%。分析师对 QURE 和 OMER 持乐观态度，价格目标暗示出显著的增长，而 SDST 最近的协议使其在锂需求上升的背景下具备未来增长的潜力</p>

<p>Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joining a rally that has room to continue is powerful.</p>
<div class="lb-trans"><p>动量投资者依赖敏锐的分析和时机组合来最大化收益。虽然这种方法可能带来相当大的风险，但识别快速增长的股票并参与一个有继续空间的上涨行情的吸引力是强大的。</p>
</div><p>The strong potential for explosive growth that characterizes the biopharmaceuticals industry makes it a primary target for many momentum investors, and two companies in that space have recently achieved significant gains. The first, uniQure N.V. NASDAQ: QURE, saw a major share price leap in late September and has worked to continue those gains in the following month. The other, Omeros Corp. NASDAQ: OMER, experienced a jump in price in mid-October.</p>
<div class="lb-trans"><p>生物制药行业所特有的爆炸性增长潜力使其成为许多动量投资者的主要目标，而该领域的两家公司最近取得了显著的收益。第一家是 uniQure N.V. NASDAQ: QURE，在九月底股价大幅跃升，并努力在接下来的一个月中继续保持这些收益。另一家是 Omeros Corp. NASDAQ: OMER，在十月中旬经历了股价的跳升。</p>
</div><p>For investors seeking diversification outside of the biotech space, Stardust Power Inc. NASDAQ: SDST is a micro-cap battery tech firm and a penny stock that has yet to begin a rally, but which enjoys astronomical upside potential based on estimates from bullish analysts.</p>
<div class="lb-trans"><p>对于寻求在生物技术领域之外进行多元化投资的投资者来说，Stardust Power Inc. NASDAQ: SDST 是一家微型市值电池技术公司，尚未开始上涨，但根据乐观分析师的估计，其潜在上行空间巨大。</p>
</div><h2>Large Pipeline and Promising Results Fuel uniQure</h2>
<div class="lb-trans"><h2>大量管线和有希望的结果推动 uniQure</h2>
</div><p>Known for its adeno-associated viral (AAV) vector platform used to design gene therapies for diseases including hemophilia, uniQure reported encouraging results for an initial safety and exploratory efficacy trial related to its AMT-191 candidate in September. The company also has a number of other drug candidates that have shown promise: its AMT-130 achieved a critical breakthrough therapy designation earlier this year and has demonstrated strong results among patients with Huntington's disease, while AMT-260 showed significant reduction of seizures in patients with a unique type of epilepsy.</p>
<div class="lb-trans"><p>uniQure 以其用于设计基因疗法的腺病毒相关病毒（AAV）载体平台而闻名，该平台用于治疗包括血友病在内的疾病。uniQure 在九月份报告了其 AMT-191 候选药物的初步安全性和探索性疗效试验的令人鼓舞的结果。该公司还有多种其他药物候选者显示出希望：其 AMT-130 在今年早些时候获得了关键的突破性疗法认证，并在亨廷顿病患者中显示出强劲的结果，而 AMT-260 在一种独特类型的癫痫患者中显示出显著减少癫痫发作的效果。</p>
</div><p>With a biotech firm that is pre-profit, as is the case for uniQure, maintaining a healthy pool of cash to sustain operations through essential development and trial phases is key. As of the end of the second quarter, the company had $377 million in cash and investments, providing a runway into 2027 and extending beyond AMT-130's projected launch period.</p>
<div class="lb-trans"><p>对于像 uniQure 这样的尚未盈利的生物技术公司来说，保持健康的现金储备以支持其在关键开发和试验阶段的运营至关重要。截至第二季度末，该公司拥有 3.77 亿美元的现金和投资，为其运营提供了持续到 2027 年的资金，并超出了 AMT-130 的预计上市时间。</p>
</div><p>QURE shares have traded horizontally since spiking in September, but analysts remain bullish. Ten out of 12 rate the stock a Buy, and collectively they expect a consensus price target of $71.75, for 15% in upside potential.</p>
<div class="lb-trans"><p>自九月激增以来，QURE 的股价一直横盘交易，但分析师们仍然持乐观态度。12 位分析师中有 10 位将该股票评级为买入，他们共同预计的共识目标价为 71.75 美元，具有 15% 的上行潜力。</p>
</div><h2>Major Novo Nordisk Deal Launches Opportunities for Omeros</h2>
<div class="lb-trans"><h2>诺和诺德重大交易为 Omeros 开启机会</h2>
</div><p>Omeros develops small-molecule and protein therapeutics for conditions related to the central nervous system. One of its most promising drugs, Zaltenibart, has the potential to address multiple blood and kidney disorders.</p>
<div class="lb-trans"><p>Omeros 开发针对中枢神经系统相关疾病的小分子和蛋白质治疗药物。其最有前景的药物之一 Zaltenibart 有潜力解决多种血液和肾脏疾病。</p>
</div><p>In mid-October, shares of the company spiked when it announced that Danish multinational pharmaceutical giant Novo Nordisk A/S NYSE: NVO had acquired licensing rights to Zaltenibart for $240 million in upfront payments and the potential for additional royalties.</p>
<div class="lb-trans"><p>在十月中旬，该公司的股价在宣布丹麦跨国制药巨头诺和诺德 A/S NYSE: NVO 以 2.4 亿美元的预付款和潜在的额外版税收购 Zaltenibart 的许可权时激增。</p>
</div><p>While this is massive news for Omeros, there may still be room to rally further. As the company now has a runway into 2027, it has additional time to pursue FDA approval for another of its top candidates, Narsoplimab.</p>
<div class="lb-trans"><p>虽然这对 Omeros 来说是个重大消息，但仍然可能有进一步上涨的空间。由于该公司现在有资金支持到 2027 年，它还有额外的时间来追求 FDA 对其另一款顶级候选药物 Narsoplimab 的批准。</p>
</div><p>Despite jumping from just over $4 per share to nearly $11 per share upon the Novo Nordisk news, OMER shares have fallen back to around $8 per share after the spike. Nonetheless, analysts are optimistic, with five out of eight calling OMER a Buy. They see upside potential of nearly 244%, which would bring OMER stock to more than $27 per share.</p>
<div class="lb-trans"><p>尽管在诺和诺德消息公布后，OMER 的股价从每股略高于 4 美元跃升至接近 11 美元，但在激增后，OMER 的股价已回落至每股约 8 美元。尽管如此，分析师们仍持乐观态度，八位分析师中有五位将 OMER 评级为买入。他们看到近 244% 的上行潜力，这将使 OMER 的股价超过每股 27 美元。</p>
</div><h2>Key Agreements and Regulatory Tailwinds Could Mean 1,000% Upside for Stardust</h2>
<div class="lb-trans"><h2>关键协议和监管利好可能意味着 Stardust 有 1000% 的上行空间</h2>
</div><p>Pre-profit biopharma firms are a risky play, but Stardust may be even more so. Just three years old and pre-revenue, this $40-million lithium battery product provider is down more than 87% this year. However, the company may be poised for growth thanks to recent agreements with Oklahoma Gas and Electric Company—the subsidiary of OGE Energy Corp. NYSE: OGE—to develop an electric substation and with Prairie Lithium to secure 6,000 metric tons of lithium carbonate per year.</p>
<div class="lb-trans"><p>尚未盈利的生物制药公司是一项风险投资，但 Stardust 可能更具风险。这家成立仅三年、尚未产生收入的 4000 万美元锂电池产品供应商今年下跌超过 87%。然而，由于与 Oklahoma Gas and Electric Company（OGE Energy Corp. NYSE: OGE 的子公司）达成的协议，开发电力变电站，以及与 Prairie Lithium 达成的协议，确保每年 6000 公吨的碳酸锂供应，该公司可能有望实现增长。</p>
</div><p>With these developments, Stardust will be closer to scaling its production at a time in which domestic demand is surging and international trade tensions are constraining the North American lithium supply.</p>
<div class="lb-trans"><p>随着这些进展，Stardust 将在国内需求激增和国际贸易紧张局势限制北美锂供应的时刻，离扩大生产更近一步。</p>
</div><p>Further, federal initiatives have helped to bolster domestic lithium producers, providing further tailwinds for companies like Stardust. This has encouraged analysts to take a boldly bullish view of SDST shares. Four out of six call SDST a Buy, and the company's price target of $51.13 is, astonishingly, almost 1,000% above where it currently trades.</p>
<div class="lb-trans"><p>此外，联邦倡议帮助增强了国内锂生产商的实力，为像 Stardust 这样的公司提供了进一步的利好。这促使分析师对 SDST 股票持大胆乐观的看法。六位分析师中有四位将 SDST 评级为买入，该公司的目标价为 51.13 美元，令人惊讶的是，几乎是其当前交易价格的 1000% 之上。</p>
</div><h2>Should You Invest $1,000 in uniQure Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 uniQure 吗？</h2>
</div><p>Before you consider uniQure, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 uniQure 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 uniQure 并不在名单上。</p>
</div><p>While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 uniQure 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

你需要知道的突破动量交易机会